Liminatus Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Research and development | — | $2.7M | — |
| Operating expenses | $3.0M | $3.3M | — |
| Operating income | -$3.0M | -$3.3M | — |
| Interest expense | $215,903 | $338,882 | — |
| Net income | -$10.2M | -$3.5M | — |
| Balance Sheet | |||
| Current assets | $500,574 | $5.3M | — |
| Total assets | $512,795 | $5.4M | — |
| Current liabilities | $10.3M | $24.7M | — |
| Total liabilities | $10.3M | $24.7M | — |
| Stockholders' equity | -$9.8M | -$19.3M | -$15.8M |
| Cash Flow Statement | |||
| Cash from operations | -$10.0M | -$1.5M | — |
| Depreciation and amortization | $1,828 | — | — |
| Capital expenditure | $13,108 | — | — |
| Free cash flow | -$10.0M | — | — |
Shares outstanding 44.9M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.